Abstract: A cDNA having a base sequence for human vascular permeability factor has been cloned and characterized and the amino acid sequence of the human vascular permeability factor protein has been determined.

Abstract: A novel and unique plasminogen activator inhibitor fragment is obtained from human umbilical vein endothelial cells which has the following characteristics:A. it is derived from a native t-PA inhibitor that binds to and inhibits the activity of t-PA,B. it is dissociated from a complex formed between said native t-PA inhibitor and t-PA, said complex existing in two distinct interconvertible conformations with molecular weight of about 88 KDa and 105 KDa, respectively, and being partially reversible in the presence of fibrin,C. it has a molecular weight of about 40 KDa when dissociated from the complex, andD. it has a novel partial N-terminal amino acid sequence when dissociated from the complex.

Abstract: Plasminogen activators (PA) are obtained from cultured normal human colon cells which are adaptable to large scale production. A purified tissue PA (t-PA) is obtained from CCD-18Co normal human colon fibroblast cells which shows chemical differences from Bowes melanoma t-PA.

Abstract: A method of producing antibodies against vascular permeability factor (VPF) is disclosed which comprises immunizing a host animal with a peptide having an amino acid sequence as follows: ##STR1## or a fragment of said peptide containing an antigenic determinant of VPF.

Abstract: A method of stimulating endothelial cell growth is provided which comprises subjecting said cells to a growth stimulating amount of a highly purified vascular permeability factor having the following characteristics:(a) it has a M.sub.r about 34,000-40,000 as determined by sodium dodecylsulfate polyacrylamide gel electrophoresis;(b) it is a disulfide-linked protein dimer;(c) it has a N-terminal amino acid sequence as follows: ##STR1## (d) it exhibits substantial mitogenic activity to endothelial cells in culture.

Abstract: A method is disclosed for increasing the yield of t-PA in culture of mammalian cells comprising introducing antibodies to the t-PA of said cells into the cell culture nutrient medium, allowing the cells to grow, and then recovering t-PA from the t-PA-antibody complex thus found in the conditioned medium by exchanging antibody in the complex for t-PA antibody immobilized on an inert support.

Abstract: Normal human colon fibroblast tissue plasminogen activator is separated by lysine-Sepharose affinity chromatography into Types I and II glycoforms and characterized with respect to the relative incidence of each type of oligosaccharide comprising the respective Types I and II glycoforms.

Abstract: A monoclonal antibody is disclosed which is specific for human colon fibroblast-derived tissue plasminogen activator (t-PA), and which is useful for immunoaffinity chromatography purification of t-PA and determination of t-PA in a biological sample.

Abstract: A monoclonal antibody is disclosed which is specific for human colon fibroblast-derived tissue plasminogen activator (t-PA), and which is useful for immunoaffinity chromatography purification of t-PA and determination of t-PA in a biological sample.

Abstract: Glycosylated plasminogen activator (t-PA) having a glycosylation pattern significantly different than exhibited by t-PA from Bowes melanoma cells is obtained from cultured normal human colon fibroblast cells (CCD-18Co).

Abstract: A monoclonal antibody is disclosed which is specific for human colon fibroblast-derived tissue plasminogen activator (t-PA), and which is useful for immunoaffinity chromatography purification of t-PA and determination of t-PA in a biological sample.

Abstract: Glycosylated plasminogen activator (t-PA) having a glycosylation pattern significantly different than exhibited by t-PA from Bowes melanoma cells is obtained from cultured normal human colon fibroblast cells (CCD-18Co).

Abstract: The disclosure relates to novel synthetic thiopeptolide substrates having high activity for the enzyme collagenase. These substrates have the following amino acid sequences:R-Pro-X-Gly-S-Y-Z-Gly-R.sub.1whereinR=H or N-protecting group,X=Leu, Ile, Phe, Val, Gln, Ala,Y=Leu, Ile, Phe, Val, Ala,Z=Leu, Ile, Phe, Val, Gln, Ala, andR.sub.1 =terminal amide, carboxyl or ester group.

Abstract: The disclosure relates to novel synthetic thiopeptolide substrates having high activity for the enzyme collagenase. These substrates have the following amino acid sequences:R-Pro-X-Gly-S-Y-Z-Gly-R.sub.1whereinR=H or N-protecting group,X=Leu, Ile, Phe, Val, Gln, Ala,Y=Leu, Ile, Phe, Val, Ala,Z=Leu, Ile, Phe, Val, Gln, Ala, andR.sub.1 =terminal amide, carboxyl or ester group.

Abstract: A method and apparatus for maintaining animal cells in vitro in a substantially arrested state of proliferation with continuous secretion of cell product is disclosed. The cells are retained within a reactor vessel chamber in a semi-rigid matrix having interstices for passage of fluid nutrient medium. Fresh nutrient medium is supplied by perfusion into the matrix through relatively low porosity tubes which are suspended in the reactor chamber and which substantially traverse the matrix; expended medium and cell product is withdrawn through relatively high porosity tubes which also are suspended in the reactor chamber and which substantially traverse the matrix; and oxygenated gaseous medium is supplied by perfusion into the matrix through a selectively-permeable membrane disposed in the reactor chamber.

Abstract: Anchorage-dependent cells are grown in agitated microcarrier suspension in which the cells and microcarriers are aggregated by periodically providing a temporary residence of said microcarriers and cells outside the main cell culture reactor agitation zone and in a separate compartment wherein they are subjected to a gentle tumbling action within a confined space having substantially the same environmental conditions as in the main cell culture reactor.

Abstract: A cell culture system and apparatus is provided for the agitated suspension culturing of mammalian cells in a flask assembly in which the culture medium and cells are gently agitated by the slow rotation of agitator means suspended downwardly in the culture medium and having at least one flexible sheet with a relatively large surface area which is positioned on the agitator in a manner to allow it to billow like a sail as liquid spills from its trailing edge during said rotation of the agitator means.

Abstract: Process for the production of human angiogenic factor in vitro comprising growing cells of human foreskin fibroblast cell line on support surface in nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate angiogenic factor and recovering the resulting angiogenic factor from the cells or cell product.

Abstract: Process for the production of human angiogenic factor in vitro comprising growing the human diploid cell line IMR-90 on support surface in nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate angiogenic factor and recovering the resulting angiogenic factor from the cells or cell product.

Abstract: A quick connect coupler for fluid transfer is disclosed in which one or both of the mating coupler members is provided with a sleeve which encloses at least a portion of said coupler member adjacent to its coupling end. The sleeve has an inlet for admission of air through its outer wall, a narrow concentric gap between its inner wall and the enclosed coupler member at said coupling end, and a passageway leading from said air inlet to said concentric gap for passage of air over said coupling end. The coupler is adapted for repeated connecting and disconnecting by cooperating releasable coupling means without loss of sterility by virtue of an air shield which is produced over said coupling end by passage of sterile air through the concentric gap.